Effect of n-3 Polyunsaturated Fatty Acids on Regression of Coronary Atherosclerosis in Statin Treated Patients Undergoing Percutaneous Coronary Intervention.
10.4070/kcj.2016.46.4.481
- Author:
Jinhee AHN
1
;
Seo Kwang PARK
;
Tae Sik PARK
;
Jin Hee KIM
;
Eunyoung YUN
;
Sang Pil KIM
;
Hye Won LEE
;
Jun Hyok OH
;
Jung Hyun CHOI
;
Kwang Soo CHA
;
Taek Jong HONG
;
Sang Yeoup LEE
;
Han Cheol LEE
Author Information
1. Division of Cardiology, Department of Internal Medicine, Pusan National University Hospital, Busan, Korea. glaraone@hanmail.net
- Publication Type:Original Article
- Keywords:
n-3 polyunsaturated fatty acids;
Atherosclerosis;
Coronary artery disease;
Statin
- MeSH:
Atherosclerosis;
Coronary Artery Disease*;
Fatty Acids, Omega-3*;
Follow-Up Studies;
Humans;
Hydroxymethylglutaryl-CoA Reductase Inhibitors*;
Percutaneous Coronary Intervention*;
Plaque, Atherosclerotic;
Stents;
Ultrasonography
- From:Korean Circulation Journal
2016;46(4):481-489
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND AND OBJECTIVES: Statins remain the mainstay of secondary coronary artery disease (CAD) prevention, but n-3 polyunsaturated fatty acids (ω-3 PUFA) display biological effects that may also reduce the risk of atherosclerosis and CAD. However, data on the possible antiatherosclerotic benefits of adding ω-3 PUFA to statin therapy are limited. This study aimed to investigate the potential additive effects of ω-3 PUFA on regression of atherosclerosis in CAD patients receiving statin therapy and stent implantation. SUBJECTS AND METHODS: Seventy-four CAD patients undergoing percutaneous coronary intervention (PCI) with stent implantation were enrolled, prescribed statins, and randomly assigned to two groups: n-3 group (ω-3 PUFA 3 g/day, n=38) or placebo group (placebo, n=36). All patients completed the study follow-up consisting of an intravascular ultrasound at baseline and at 12 months. RESULTS: There was no difference in the baseline characteristics and distribution of other medications. No significant differences were observed in primary endpoints, including changes in atheroma volume index (-12.65% vs. -8.51%, p=0.768) and percent atheroma volume (-4.36% vs. -9.98%, p=0.526), and in secondary endpoints including a change in neointimal volume index (7.84 vs. 4.94 mm3/mm, p=0.087). CONCLUSION: ω-3 PUFA had no definite additional effect on the regression of coronary atherosclerosis when added to statin in CAD patients undergoing PCI.
